Wednesday, December 23, 2015 7:22:57 AM
Piper Jaffray analyst Joshua Schimmer views Celgene's settlement with Natco for the Revlimid Paragraph IV patent challenge as "creative and a positive." The news removes the overhang that allows the company to continue managing towards 25% annual earnings growth through the middle of the next decade, Schimmer tells investors in a research note. The agreement allows a limited generic launch in 2022, the analyst points out. Celgene remains one of his top biotech picks with an Overweight rating and $163 price target
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM